FDA Signals uniQure Huntington Gene Therapy Data Could Back Accelerated Approval - uniQure (NASDAQ:QURE)

UniQure to file gene therapy for approval, reflecting major shifts at FDA

The decision marks another regulatory U-turn following the exits of Marty Makary and Vinay Prasad, suggesting to some analysts that current FDA leadership may be more flexible in certain cases.